High content screening for nonclassical peroxisome proliferators

References

• Heymans HS, Schutgens RB, Tan R, et al. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature. 1983;306(5938):69–70.
   Web of Science ®Google Scholar
• Shimozawa N, Tsukamoto T, Suzuki Y, et al. A human gene responsible for Zellweger syndrome that affects peroxisome assembly. Science. 1992;255(5048):1132–1134.
   Web of Science ®Google Scholar
• Song S. The role of increased liver triglyceride content: a culprit of diabetic hyperglycaemia? Diabetes Metab Res Rev. 2002;18(1):5–12.
   Web of Science ®Google Scholar
• Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. CurrDiab Rep. 2006;6(3):177–181.
   Google Scholar
• Reddy JK, Krishnakantha TP. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. Science. 1975;190(4216):787–789.
   Web of Science ®Google Scholar
• Fujita T, Sugiyama Y, Taketomi S, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes. 1983;32(9):804–810.
   Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43(4):527–550.
   PubMed Web of Science ®Google Scholar
• Guerre-Millo M, Gervois P, Raspe E, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity, J Biol Chem. 2000;275(22):16638–16642.
   PubMed Web of Science ®Google Scholar
• Clouet P, Henninger C, Niot I, et al. Short term treatment by fenofibrate enhances oxidative activities towards long-chain fatty acids in the liver of lean Zucker rats. Biochem Pharmacol. 1990;40(9):2137–2143.
   Web of Science ®Google Scholar
• Chaput E, Saladin R, Silvestre M, et al. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000;271(2):445–450.
   Web of Science ®Google Scholar
• Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137–1140.
   PubMed Web of Science ®Google Scholar
• Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51.
   PubMed Web of Science ®Google Scholar
• Basseri S, Lhotak S, Sharma A, et al. The chemical chaperone 3- phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. The Journal of Lipid Research. 2009;50(12):2486–2501.
   PubMed Web of Science ®Google Scholar
• Gondcaille C, Depreter M, Fourcade S, et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol. 2005;169(1):93–104.
   Web of Science ®Google Scholar
• Neuberger G, Maurer-Stroh S, Eisenhaber B, et al. Prediction of peroxisomal targeting signal 1 containing proteins from amino acid sequence. J Mol Biol. 2003;328(3):581–592.
   PubMed Web of Science ®Google Scholar
• Grabenbauer M, Satzler K, Baumgart E, et al. Three-dimensional ultra-structural analysis of peroxisomes in HepG2 cells. Cell Biochemistry andBiophysics. 2000;32(1):37–49.
   Google Scholar
• Kobayashi K, Inoguchi T, Maeda Y, et al. The lack of the C-terminal domain of adipose triglyceride lipase causes neutral lipid storage disease through impaired interactions with lipid droplets. J Clin Endocrinol Metab. 2008;93(7):2877–2884.
   Web of Science ®Google Scholar
• Schrader M, Krieglstein K, Fahimi HD. Tubular peroxisomes in HepG2 cells: selective induction by growth factors and arachidonic acid. Eur J Cell Biol. 1998;75(2):87–96.
   Web of Science ®Google Scholar
• Baes M, Gressens P, Baumgart E, et al. A mouse model for Zellweger syndrome. Nature Genetics. 1997;17(1):49–57.
   Web of Science ®Google Scholar
• Gray RH, and de la Iglesia FA. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology. 1984;4(3):520–530.
   Web of Science ®Google Scholar
• Hoivik DJ, Qualls CW Jr, Mirabile RC, et al. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis. 2004;25(9):1757–1769.
   Web of Science ®Google Scholar
• Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007;125(3):451–472.
   PubMed Web of Science ®Google Scholar
• Schrader M, Fahimi HD. Mammalian peroxisomes and reactive oxygen species. Histochem Cell Biol. 2004;122(4):383–393.
   PubMed Web of Science ®Google Scholar
• Wang C, Harris W S, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84(1):5–17.
   PubMed Web of Science ®Google Scholar
• Ferdinandusse S, Denis S, Mooijer PA, et al. Identification of the peroxisomal beta-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid. J Lipid Res. 2001;42(12):1987–1995.
   Web of Science ®Google Scholar
• Moore SA, Hurt E, Yoder E, et al. Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. J Lipid Res. 1995;36(11):2433–2443.
   Web of Science ®Google Scholar
• Steinberg SJ, Dodt G, Raymond GV et al. Peroxisome biogenesis disorders. Biochim Biophys Acta. 2006;1763(12):1733–1748.
   PubMed Web of Science ®Google Scholar